Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review

Clinical and Translational Medicine

Table 1 Trials about the efficacy of first- and second-generation ALK inhibitors

Study	Phase of study	Treatment	Number of patients	ORR (%)	PFS (months)	Patient population	References
PROFILE 1001	I	Crizotinib	149	60.8	10	125 of 149 ALK rearranged patients had disease progression on ≥ 1 chemotherapy	[5]
PROFILE 1005	II	Crizotinib	261	60	8.1	ALK rearranged patients had disease progression on ≥ 1 chemotherapy	[6]
PROFILE 1007	III	Crizotinib vs docetaxel or pemetrexed	173 174	65 20	7.7 3.0	ALK rearranged patients previously treated with chemotherapy (platinum doublet)	[11]
PROFILE 1014	III	Crizotinib vs pemetrexed +cispaltin/carboplatin	172 171	74 45	10.9 7.0	Treatment-naive ALK rearranged patients	[12]
ASCEND3	II	Ceritinib	124	63.7	11.1	ALK rearranged patients ALK inhibitor-naive but had disease progression on chemotherapy.	[13]
ASCEND4	III	Ceritinib vs pemetrexed +cispaltin/carboplatin	189 187	72.5 26.7	16.6 8.1	Treatment-naive ALK rearranged patients	[14]
ASCEND5	III	Ceritinib vs docetaxel or pemetrexed	231 116	39.1 6.9	5.4 1.6	ALK rearranged patients previously treated With chemotherapy (platinum doublet) and crizotinib	[15]
J-ALEX	III	Crizotinib vs alectinib	104 103	70.2 85.4	10.2 20.3—not reached	Treatment-naive ALK rearranged patients	[16]
NP28763	II	Alectinib	138	50	8.9	ALK rearranged patients previously treated with chemotherapy and crizotinib	[17]
NP28761	II	Alectinib	87	52.2	8.1	ALK rearranged patients previously treated with chemotherapy and crizotinib	[18]